Evaluation of matrix metalloproteinase-2 in lung cancer

Proteomics - Clinical Applications

Volumn 8, Issue 3-4, 2014, Pages 251-257

  Ali Labib, Randa ^a   Louka, Manal Louis ^a   Galal, Iman Hassan El Sayed ^a   Tarek, Marwa ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Lung cancer; Metastasis; MMP 2; Serum; Sputum; Zymography

Indexed keywords

GELATINASE A; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPUTUM ANALYSIS; VERY ELDERLY; ZYMOGRAPHY; BLOOD; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SPUTUM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SPUTUM; TUMOR MARKERS, BIOLOGICAL;

EID: 84898546490     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300086     Document Type: Article

References (39)

1. Chlebowski, R. T., Schwartz, A., Wakelee, H., Anderson, G. L. et al., Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial. J. Clin. Oncol. 2009, 27, 18s.
2. Hernández-García I., Sáenz-González, M., González-Celador, R., Mortality attributable to smoking in Spain in 2006. An. Sist. Sanit. Navar 2010, 33, 23-33.
3. Tammemagi, C. M., Pinsky, P. F., Caporaso, N. E., Kvale, P. A. et al., Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J. Natl. Cancer Inst. 2011, 103, 1058-1068.
4. Curado, M. P., Edwards, B., Shin, H. R., Storm, H. (Eds.), Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications, No. 160, Lyon 2007, pp. 829-835.
5. Basset, P., Okada, A., Cenard, M. P., Kannan, R. et al., Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutical implications. Matrix Biol. 1997, 15, 535-541.
6. Johnsen, M., Lund, L. R., Romer, J., Almholt, K. et al., Cancer invasion and tissue remodelling: common themes in proteoglytic matrix. Curr. Opin. Cell Biol. 1998, 10, 667-671.
7. Leeman, M. F., Curran, S., Murray, G. I., New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J. Pathol. 2003, 201, 528-534.
8. Herbst, R. S., Yano, S., Kuniyasu, H., Khuri, F. R. et al., Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin. Cancer Res. 2000, 6, 790-797.
9. Pan, M. R., Chuang, L. Y., Hung, W. C., Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett. 2001, 508, 365-368.
10. Gohji, K., Fujimoto, N., Komiyama, T., Fujii, A. et al., Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictor of recurrence in patients with orothelial carcinoma. Cancer 1996, 78, 2379-2387.
11. Dragonieri, S., Tongoussouva, O., Zanini, A., Imperatori, A. et al., Markers of airway inflammation in pulmonary diseases assessed by induced sputum. Monaldi Arch. Chest Dis. 2009, 71, 119-126.
12. Keatings, V. M., Collins, P. D., Scott, D. M., Barnes, P. J., Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996, 153, 530-534.
13. Jackson, P. L., Xu, X., Wilson, L., Weathington, N. M. et al., Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. Mol. Med. 2010, 16, 159-166.
14. Sambrook, J., Fritsch, E. F., Maniatis, T., Molecular Cloning: A Laboratory Manual, 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1989, pp. 16-42.
15. Heussen, C., Dowdle, E. B., Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 1980, 102, 196-202.
16. Bianco F. J. Jr., Gervasi, D. C., Tiguert, R., Grignon, D. J. et al., Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin. Cancer Res. 1998, 4, 3011-3016.
17. Bergers, G., Brekken, R., McMahon, G., Vu, T. H. et al., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2, 737-744.
18. Fang, J., Shing, Y., Wiedereschain, D., Yan, L. et al., Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 3884-3889.
19. Garbisa, S., Scagliotti, G., Masiero, L., Di Francesco, C. et al., Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 1992, 52, 4548-4549.
20. Oncel, M., Akoz, M., Oncel, M., Kiyici, A. et al., MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels in epidermoid lung cancer. Turk. J. Med. Sci. 2012, 42, 1203-1261.
21. Eren, B., Sar, M., Oz, B., Dincbas, F., MMP-2, TIMP-2 and CD44v6 in non-small cell lung carcinomas. Ann. Acad. Med. Singapore 2008, 37, 32-39.
22. Thomas, P., Khokha, R., Shepherd, F. A., Feld, R. et al., Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol. 2000, 190, 150-156.
23. Ishikawa, S., Takenaka, K., Yanagihara, K., Miyahara, R. et al., Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin. Cancer Res. 2004, 10, 6579-6585.
24. Leinonen, T., Pirinen, R., Böhm, J., Johansson, R. et al., Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol. Histopathol. 2008, 23, 693-700.
25. Iniesta, P., Morán, A., De Juan, C., Gómez, A. et al., Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol. Rep. 2007, 17, 217-223.
26. Yamamura, T., Nakanishi, K., Hiroi, S., Kumaki, F. et al., Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in non-small cell lung carcinomas. Lung Cancer 2002, 35, 249-255.
27. Yurdakul, A. S., Akyürek, N., Yilmaz, S., Karakaya, J. et al., Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growth factor expression in non-small cell lung cancer. Turk. J. Med. Sci. 2012, 42, 281-288.
28. Passlick, B., Sienel, W., Seen-Hibler, R., Wöckel, W. et al., Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin. Cancer Res. 2000, 6, 3944-3948.
29. Hida, Y., Hamada, J., Differential expressions of matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs and their endogenous inhibitors among histologic subtypes of lung cancers. Anticancer Agents Med. Chem. 2012, 12, 744-752.
30. Visse, R., Nagase, H., Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92, 827-839.
31. Lee, W. Y., Huang, S. C., Tzeng, C. C., Chang, T. L. et al., Alterations of metastasis-related genes identified using an oligonucleotide microarray of genistein treated HCC1395 breast cancer cells. Nutr. Cancer 2007, 58, 239-246.
32. Gravitz, L., Chemoprevention: first line of defence. Nature 2011, 471, S5-7.
33. Coussens, L. M., Werb, Z., Inflammation and cancer. Nature 2002, 420, 860-867.
34. Anderson, G. P., Bozinovski, S., Acquired somatic mutations in the molecular pathogenesis of COPD. Trends Pharmacol. Sci. 2003, 24, 71-76.
35. Ballaz, S., Mulshine, J. L., The potential contributions of chronic inflammation to lung carcinogenesis. Clin. Lung Cancer 2003, 5, 46-62.
36. Schabath, M. B., Delclos, G. L., Martynowicz, M. M., Greisinger, A. J. et al., Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am. J. Epidemiol. 2005, 161, 412-422.
37. Zandwijk, N. V., Aetiology and prevention of lung cancer. Eur. Respir. Monogr. 2001, 17, 13-33.
38. Hrabec, E., Strek, M., Nowak, D., Greger, J. et al., Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J. Cancer Res. Clin. Oncol. 2002, 128, 197-204.
39. Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D. A., Delgado, J. et al., Gelatinase activity of matrix metalloproteinases during first-line chemotherapy in lung adenocarcinoma patients: an initial approach. Lung 2012, 190, 99-104.